Neoleukin Therapeutics emerged from the University of Washington Institute for Protein Design in January of 2019. We are creating next generation immunotherapies using breakthrough de novo protein design technology. We use natural protein complexes as inspiration to develop custom designed proteins with superior pharmaceutical properties.
Location: United States, Washington, Seattle
Employees: 51-200
Founded date: 2019
Investors 2
| Date | Name | Website |
| - | WRF Capita... | wrfseattle... |
| - | Sahsen Ven... | sahsen.com |
Mentions in press and media 5
| Date | Title | Description |
| 08.11.2025 | Accipiter Biosciences Secures $12.7M Seed Funding, Revolutionizing Protein Therapies | Accipiter Biosciences, a Seattle biotech, exited stealth with $12.7 million in seed funding. The company pioneers de novo multifunctional protein therapeutics. Its computational platform designs novel biologics from scratch. These single mo... |
| 07.11.2025 | Accipiter Biosciences: $12.7 Million Seed Funding Closed To Develop De Novo Protein Therapies | Accipiter Biosciences has emerged from stealth with $12.7 million in seed funding to advance a new class of de novo multifunctional protein therapeutics designed to treat complex diseases. The seed round was co-led by Takeda and Flying Fish... |
| 12.12.2021 | Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd American Society of Hematology Annual Meeting (ASH 2021) | – Poster presentation highlights NL-201 activity in multiple myeloma stem cell transplant model – – Abstract reports activity of NL-201 as monotherapy and anti-PD1 combination in non-Hodgkin lymphoma model – SEATTLE, Dec. 11, 2021 (GLOBE NE... |
| 19.11.2020 | How One Company Pivoted From Cancer To Coronavirus And Designed A Virus-Blocking Drug In 10 Weeks | When the pandemic arrived in the United States, millions of us were sidelined by stay-at-home orders, unable to go in to work but not quite sure how to be productive from home. We baked mountains of bread, deep-cleaned our apartments, or bi... |
| 06.08.2019 | Cancer-fighting startup Neoleukin merging with Aquinox in $40M deal, 8 months after UW spinout | Neoleukin Therapeutics launched in January with the goal of commercializing a cancer-fighting protein that was designed from scratch at the University of Washington. (UW Photo) Vancouver, B.C.-based Aquinox Pharmaceuticals is set to buy Neo... |